drugset / Trial / NCT05100134

Managed Access Programs for LDK378, Ceritinib

NCT05100134

Expanded access No longer available Novartis Pharmaceuticals

Summary

The purpose of this registration is to list Managed Access Programs (MAPs) related to LDK378, Ceritinib.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background Ceritinib Small molecule Oral